|
Greater China Consortium for Study of Hepatitis B Virus Immunopathogenesis and Immunity (GC-CS-HBVII)
- Greater China
- Non-profit
- Non-discriminatory
- Non-political
Our Vision
“Perfect” tailor made therapy for chronic hepatitis B
Our Mission
To offer innovative integrated molecular diagnostic and research approaches for the clinical management of chronic hepatitis B
Goals of HBV study
- To identify predictors of disease progression and treatment response
- To develop new therapies for viral hepatitis and liver cancer
- To promote high quality research into viral hepatitis
- To consolidate Greater China partnerships with clinical, genetic, virological and immunological expertise
- To develop a comprehensive bioinformatics resource for the management of chronic hepatitis B
Founding Institutes
Advisor |
Eddy F.Y. Liew |
University of Glasgow, UK |
| |
|
Beijing 302 Hospital |
Members |
Fu-Sheng Wang |
Beijing Institute of Infectious Diseases |
|
George Fu Gao |
Chinese Academy of Sciences (IMCAS) |
|
Xiao-Ming Gao |
Peking University Health Science Centre |
|
Fang-Ping Huang |
University of Hong Kong |
|
George KK Lau |
University of Hong Kong |
|
